Loading news...
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
Theravance Bio (TBPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to a loss of $0.05 per share a year ago.
Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starting in Q3 2026 Strategic Review Committee accelerating evaluation of opportunities to maximize shareholder value YUPELRI ® achieved record brand profitability for Q4 and full-year 2025; full-year net sales of $266.6 million, recognized by Viatris, up 12% year-over-year 1 resulting in a $25 million milestone payment Full-year 2025 TRELEGY net sales, reported by GSK, of $3.9 billion, up 12% year-over-year, triggered a $50 million milestone payment; high confidence in achieving the $100 million 2026 milestone payment 2 All-time high non-GAAP profitability achieved for the second consecutive quarter 3 Company expects to have approximately $400 million in cash at the end of Q1 2026 and no debt DUBLIN, March 19, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the fourth quarter and full year of 2025. "We ended 2025 on a positive note from a financial perspective, achieving another record quarter of non-GAAP profitability, hitting a new all-time high for YUPELRI® brand-level profitability, and reaching $75 million in key sales-based milestones.
Theravance Biopharma Reaffirmed Financial Guidance Repeatedly Without Disclosing the Material Risk That Its Pivotal Trial Could Fail NEW YORK, March 18, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% when shares collapsed on March 3, 2026. In the quarters leading up to that drop, management reaffirmed financial guidance -- including $75 million in near-term milestone targets -- without quantifying the risk that a negative CYPRESS Phase 3 readout could materially impair the Company's outlook.
Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment NEW YORK, March 11, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders who lost money are encouraged to submit their information now.
New York, New York--(Newsfile Corp. - March 10, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Theravance Biopharma, Inc. ("Theravance Biopharma, Inc.") (NASDAQ: TBPH) concerning potential violations of the federal securities laws. On the Q3 2025 earnings call (November 10, 2025), CEO Rick Winningham stated the Company was "on track to achieve near-term milestones totaling $75 million in the fourth quarter -- $50 million for Trelegy and $25 million for YUPELRI.
Theravance Bio (TBPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Theravance Biopharma, Inc. (NASDAQ: TBPH - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Theravance Biopharma shares plummet 26% after its phase III CYPRESS study of ampreloxetine missed key endpoints, prompting the company to halt the program.
Theravance Biopharma Inc. (NASDAQ: TBPH) shares are tumbling on Tuesday following the company's Phase 3 CYPRESS study did not meet its primary endpoint.
Theravance Biopharma said it could be for sale Tuesday after its Phase 3 effort to treat a rare disease flopped. The biotech stock crashed.
The company is working with Lazard on a potential sale after its lead drug candidate disappointed in a late-stage study Theravance Biopharma shares collapsed 26% in morning trading on Tuesday after the company said it was exploring a potential sale following the failure of its most advanced drug candidate in a late-stage clinical trial. The company said ampreloxetine, which was being tested in patients with multiple system atrophy, a rare and progressive neurological condition that can cause a dangerous fall in blood pressure upon standing, failed to demonstrate a meaningful improvement in symptoms compared with patients receiving a placebo.
Theravance Biopharma said on Tuesday it is initiating a strategic review, including a possible sale of the company, after its experimental drug to treat a type of blood pressure disorder failed to meet the main goal in a late-stage study.
Phase 3 CYPRESS study did not meet the primary endpoint , the OHSA Composite Score, a patient reported outcome (PRO) Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at end of Q1 2026 including receipt of 2025 milestones; Theravance highly confident in achieving $100 million 2026 TRELEGY milestone 1 Strategic Review Committee accelerating ongoing efforts to evaluate alternatives to maximize shareholder value Organizational restructuring to reduce cost base by approximately 60% (or approximately $70 million); expected to result in the Company generating approximately $60 - $70 million of annualized cash flow Streamlined portfolio focused on YUPELRI®, a growing product to treat COPD with durable cash-flow generation and long-dated intellectual property protection in the U.S. into 2039; FY 2025 net sales $266.6 million recognized by Viatris (+12% YoY) 2 DUBLIN, March 3, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced topline results from the Phase 3 CYPRESS study evaluating the efficacy and safety of ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA), a rare disease. The study did not meet its primary endpoint in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score.
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
Hillsdale Investment Management Inc. acquired a new stake in Theravance Biopharma, Inc. (NASDAQ: TBPH) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 310,700 shares of the biopharmaceutical company's stock, valued at approximately $4,536,000. Hillsdale Investment Management
Theravance Biopharma (NASDAQ: TBPH - Get Free Report) and Amylyx Pharmaceuticals (NASDAQ: AMLX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Profitability This table compares Theravance Biopharma and